Fluticasone Furoate-Umeclidinium-Vilanterol 100mcg-62.5mcg-25mcg Inhaler

What Is Fluticasone Furoate + Umeclidinium + Vilanterol Inhaler (100/62.5/25 mcg)

This combination inhaler contains three medicines:_x000B_ Fluticasone furoate + Umeclidinium + Vilanterol

It is used as a maintenance treatment for chronic lung diseases such as COPD (Chronic Obstructive Pulmonary Disease) and sometimes severe asthma in adults.

COPD is a long-term condition where the airways become narrow, inflamed, and filled with mucus. This makes breathing difficult, especially during physical activity. Patients may feel breathless, have chronic cough, or experience chest tightness.

This inhaler is not for sudden breathing attacks. It is used daily to improve long-term breathing control and reduce flare-ups.

What This Medicine Does in the Body

This inhaler works by targeting three different problems in the lungs at the same time: inflammation, airway tightening, and airflow restriction.

Fluticasone furoate reduces inflammation inside the airways. In COPD, the airway lining becomes swollen and irritated. Fluticasone calms this inflammation, making breathing easier over time and reducing flare-ups.

Umeclidinium works by relaxing the muscles around the airways. In COPD, these muscles tighten and make the airway narrow. Umeclidinium blocks signals that cause tightening, allowing the airways to stay open longer.

Vilanterol helps relax airway muscles in a different way. It stimulates receptors that open the airways and improve airflow into and out of the lungs.

Together, these three medicines reduce inflammation, open airways, and improve breathing efficiency.

Uses of Fluticasone Furoate–Umeclidinium–Vilanterol Inhaler / Used For

Doctors prescribe this triple combination inhaler mainly for moderate to severe COPD in adults.

Fluticasone furoate + Umeclidinium + Vilanterol helps reduce symptoms like breathlessness, chronic cough, and chest tightness.

It also helps reduce the frequency of COPD flare-ups, which are sudden worsening of breathing symptoms that may require hospital care.

In some patients with severe asthma who are not controlled with single or dual inhalers, doctors may also consider this combination under strict supervision.

This inhaler is meant for long-term daily use, not for emergency relief.

How This Inhaler Works

This inhaler works in a three-step mechanism inside the lungs.

Fluticasone furoate reduces inflammation in the airway lining. This decreases swelling and mucus production, making airflow smoother.

Umeclidinium blocks muscarinic receptors that normally cause airway muscles to tighten. When these signals are blocked, the airway muscles relax and stay open longer.

Vilanterol activates beta2 receptors in the lungs, which also helps relax airway muscles and improves airflow.

When combined, these actions make breathing easier, reduce chest tightness, and improve oxygen flow into the lungs.

Because it is a long-acting inhaler, it provides control throughout the day with regular use.

Side Effects of Fluticasone Furoate–Umeclidinium–Vilanterol Inhaler

Like all inhaled medicines, this combination may cause side effects, especially during early use.

Fluticasone furoate may cause throat irritation, hoarseness, or oral fungal infection (thrush) if the mouth is not rinsed after use.

Umeclidinium may cause dry mouth, constipation, or mild urinary difficulty in some patients.

Vilanterol may sometimes cause fast heartbeat, mild tremors, or headache.

Less common side effects include cough, dizziness, or mild chest discomfort.

Rare but serious effects include worsening breathing symptoms, allergic reactions, or eye pressure changes in sensitive patients.

Doctors usually monitor lung function regularly to ensure safe and effective use.

Medical Disclaimer

This content is for educational purposes only. It does not replace medical advice, diagnosis, or treatment. Always consult a pulmonologist or healthcare professional before using Fluticasone furoate + Umeclidinium + Vilanterol. Use this inhaler only as prescribed for safe and effective long-term management of COPD or asthma.